Dr. McCool has over 20 years of biotech experience with 15 years working for contract development and manufacturing organizations (CDMOs). Jesse is the CEO and Co-Founder of Wheeler Bio, a customer-first CDMO which integrates the discovery, optimization, and development stages of new biological entities enabling best-in-class delivery of preclinical and clinical materials to IND sponsors. Jesse previously held technical and executive leadership positions at Lonza, Mascoma (Lallemond) and Cytovance Biologics where he helped to position the company for growth and M&A. Following the 2015 acquisition by Hepalink, Jesse served as Cytovance board director, CTO and CEO while supporting global integration and corporate strategy. He left Cytovance following the successful 2020 Hong Kong listing (SZSE:002399, HKEx:9989). Jesse earned a Ph.D. in Microbiology from the University of Massachusetts at Amherst in 2003. He completed his postdoctoral work at Dartmouth College Thayer School of Engineering (Hanover, NH) and additional technical training at the Delft University of Technology (The Netherlands). In addition to his industry experience, Jesse is an established public speaker, researcher and peer-reviewed journal author and contributor.